
Jamie E. Chaft, MD
Medical Oncologist
Clinical Expertise
Non-Small Cell Lung Cancer; Early-Stage Non-Small Cell Lung Cancer; Multilmodality Therapies
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Chaft accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
- 646-608-3761 Office Phone
- Speaks English
- New York City
- Memorial Sloan Kettering Monmouth Middletown, NJ

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, New York University School of Medicine
Residencies
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Fellowships
Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist who specializes in caring for patients with lung cancer. I am part of a team of physicians from multiple disciplines — including thoracic surgery, radiation oncology, pathology, pulmonology, and interventional radiology — who meet weekly and collaborate to determine the optimal treatment plan for our patients. As part of our suite of treatment options, my colleagues and I run and participate in a multitude of clinical trials, all of which are available to patients who qualify and wish to participate. These trials range from therapeutic trials evaluating new treatment approaches to translational trials that help us learn more about lung cancer.
Read more
In the clinic, my team and I focus on personalizing our care for each patient not only to his or her type of cancer and its genetics but to the patient’s personal circumstances, beliefs, and wishes. We consider a patient’s disease characteristics and biological characteristics in light of the priorities of each patient and his or her family, and discuss treatment options — including clinical trial opportunities when appropriate — to provide the best care for our patients as we work with them to fight their cancer.
While I care for patients with all types and stages of lung cancer, my research focuses on the use of multimodality therapies (such as chemotherapy, immunotherapy, or targeted therapy plus radiation or surgery) to improve cure rates in patients with early-stage non-small cell lung cancer.
At Memorial Sloan Kettering, I am a lead investigator on all trials evaluating multimodality treatment for non-small cell lung cancers. These trials focus on developing new treatment regimens by finding different applications for standard drugs or testing new therapeutic agents with surgery and/or radiation. Additionally, I conduct research to identify biomarkers that are unique to a patient or his or her cancer. These biomarkers can be used to preferentially select a drug treatment regimen that is likely to be more effective against that individual’s lung cancer. Discovering such biomarkers will allow us to optimize the use of available therapies to maximize the benefit of anticancer treatments while minimizing the patient’s exposure to side effects of less-active treatments. This is a promising and active research niche in the area of personalized medicine where we aim to improve the outcomes and quality of life of patients diagnosed with lung cancer.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Chaft
- A Phase II Study of Alectinib, Entrectinib, or Vemurafenib/Cobimetinib Therapy Before Surgery in Patients with Nonmetastatic Non-Small Cell Lung Cancer with Certain Molecular Changes
- A Phase III Study of MK-7684 with Pembrolizumab Immunotherapy (MK-7684A) versus Pembrolizumab Alone as Initial Treatment for Metastatic Non-Small Cell Lung Cancer
- A Phase III Study of Pre-surgical Chemotherapy and Durvalumab to Treat Operable Stage II/III Non-Small Cell Lung Cancer
- A Phase III Study of Presurgical Osimertinib Alone or with Chemotherapy versus Chemotherapy Alone for Patients with EGFR Mutation-Positive Operable Non-Small Cell Lung Cancer
Read more
- A Randomized Phase II Study of Tiragolumab plus Atezolizumab and Standard Chemotherapy versus Placebo plus Pembrolizumab and Standard Chemotherapy in People with Advanced Non-Squamous Non-Small Cell Lung Cancer
- Clinical Trials Co-Investigated by Dr. Chaft
- A Phase II Study of Canakinumab with Chemotherapy, Radiation Therapy, and Durvalumab in People with Lung Cancer
- A Phase II Study of Durvalumab Immunotherapy and Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
- A Phase II Study of Several Radiation Doses Added to Immunotherapy in Patients Whose Cancers Grew While Receiving Immunotherapy
- A Phase II Study to See if Durvalumab with Concurrent Radiation Therapy Can Prevent the Growth of Non-Small Cell Lung Cancer
- A Phase III Study Assessing the Addition of Atezolizumab Immunotherapy to the Usual Radiation Treatment for Patients with Early Non-Small Cell Lung Cancer
- A Phase III Study of Chemotherapy with Either Proton Therapy or Conventional Photon Radiation Therapy to Treat Inoperable Stage II-IIIB Non-Small Cell Lung Cancer

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Chaft’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedDisclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jamie E. Chaft discloses the following relationships and financial interests:
-
AstraZeneca
Provision of Services -
Clinical Care Options
Provision of Services -
Flame Biosciences, Inc.
Provision of Services -
Genentech
Provision of Services -
Imedex, Inc.
Provision of Services -
MJH Associates
Provision of Services -
Merck KGaA
Provision of Services
-
Novartis
Provision of Services -
OncLive
Provision of Services -
PeerView Institute for Medical Education (PVI)
Provision of Services -
Physicians' Education Resource
Provision of Services -
Practice Point Communications, LLC
Provision of Services -
Shanghai JoAnn Medical Technology Co., Ltd
Provision of Services -
i3 Health
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].